S&P 500
(0.11%) 5 254.35 points
Dow J
(0.12%) 39 807 points
Nasdaq
(-0.12%) 16 379 points
Oil
(2.16%) $83.11
Gas
(1.98%) $1.752
Gold
(1.90%) $2 254.80
Silver
(1.41%) $25.10
Platinum
(1.45%) $922.85
USD/EUR
(0.36%) $0.927
USD/NOK
(0.72%) $10.85
USD/GBP
(0.10%) $0.792
USD/RUB
(0.14%) $92.57

Realtime updates for SAGE Therapeutics Inc [SAGE]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
BUY
85.71%
return 13.30%
SELL
25.00%
return 4.12%
Last Updated28 Mar 2024 @ 16:00

-1.58% $ 18.74

BUY 62220 min ago

@ $26.76

Issued: 14 Feb 2024 @ 12:06


Return: -29.97%


Previous signal: Feb 14 - 09:30


Previous signal: Sell


Return: 6.23 %

Live Chart Being Loaded With Signals

Commentary (28 Mar 2024 @ 16:00):

Warning: Trying to access array offset on null in /home/getagraph/public_html/stock.php on line 302

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults...

Stats
Today's Volume 885 054
Average Volume 955 470
Market Cap 1.13B
EPS $0 ( 2024-02-14 )
Next earnings date ( $-1.640 ) 2024-05-07
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -2.07
ATR14 $0.0240 (0.13%)
Insider Trading
Date Person Action Amount type
2024-02-13 Greene Barry E Buy 168 000 Stock Option (Right to Buy)
2024-02-13 Cook Anne Marie Buy 11 250 Common Stock
2024-02-13 Cook Anne Marie Buy 22 500 Stock Option (Right to Buy)
2024-02-13 Gault Laura Buy 22 500 Stock Option (Right to Buy)
2024-02-13 Gault Laura Buy 11 250 Common Stock
INSIDER POWER
92.24
Last 97 transactions
Buy: 1 228 960 | Sell: 86 892

Volume Correlation

Long: 0.27 (neutral)
Short: 0.22 (neutral)
Signal:(57.475) Neutral

SAGE Therapeutics Inc Correlation

10 Most Positive Correlations
RGLD0.868
ISEM0.866
GTH0.86
SOCL0.859
MATW0.857
SGII0.856
HCM0.854
IIIV0.854
MCHI0.853
GAME0.852
10 Most Negative Correlations
LLNW-0.876
AMGN-0.859
EA-0.841
LAWS-0.835
AHPI-0.812
ASPS-0.812
AUID-0.811
CNET-0.806
ODT-0.804
HCAQ-0.801

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

SAGE Therapeutics Inc Correlation - Currency/Commodity

The country flag -0.13
( neutral )
The country flag 0.02
( neutral )
The country flag 0.00
( neutral )
The country flag 0.04
( neutral )
The country flag 0.00
( neutral )
The country flag 0.41
( neutral )

SAGE Therapeutics Inc Financials

Annual 2023
Revenue: $86.46M
Gross Profit: $84.30M (97.50 %)
EPS: $-9.05
Q4 2023
Revenue: $77.97M
Gross Profit: $77.15M (98.95 %)
EPS: $-0.550
Q3 2023
Revenue: $2.72M
Gross Profit: $1.81M (66.68 %)
EPS: $-3.37
Q2 2023
Revenue: $2.47M
Gross Profit: $2.27M (91.71 %)
EPS: $-2.68

Financial Reports:

No articles found.

SAGE Therapeutics Inc

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators